Here’s some more pressure on ceo Jeff Kindler and his new cfo, Frank D’Amelio. Goldman Sachs, one of the Street’s biggest firms, downgraded Pfizer stock and removed the drugmaker from its “Americas conviction” list, citing the stock’s under performance and a lack of near-term events to boost the value of the shares.

The brokerage cut its rating to “neutral” from “buy,” noting that Pfizer’s share price has fallen 28.7 percent since Jan. 4, 2007, versus a 2.9 percent decline in the Standard & Poor’s 500 Index SPX, Reuters reports.

Goldman further cut its price target on Pfizer to $22 from $26 as near-term pipeline products decrease in value and recent safety issues pressure the brokerage’s forecasts for the drugmaker’s anti-smoking drug Chantix, which has been linked to a large number of serious injuries and neuropsychiatric side effects, and the Sutent cancer drug, which has been linked to heart failure.